33354676|t|Propofol-Associated Hypertriglyceridemia in Coronavirus Disease 2019 Versus Noncoronavirus Disease 2019 Acute Respiratory Distress Syndrome.
33354676|a|OBJECTIVES: To characterize the incidence and characteristics of propofol-associated hypertriglyceridemia in coronavirus disease 2019 versus noncoronavirus disease 2019 acute respiratory distress syndrome. DESIGN: Single-center prospective, observational cohort study. SETTING: Medical ICU and regional infectious containment unit. PATIENTS: Patients with acute respiratory distress syndrome admitted from April 7, 2020, to May 15, 2020, requiring continuous propofol administration. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of 50 patients enrolled, 54% had coronavirus disease 2019 acute respiratory distress syndrome. Median Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores were 35.5 (interquartile range, 30.2-41) and 8 (interquartile range, 6-9). Pao2/Fio2 ratio was 130.5 (interquartile range, 94.5-193.8). Patients with coronavirus disease 2019-associated acute respiratory distress syndrome experienced a higher rate of hypertriglyceridemia (triglyceride >= 500 mg/dL) than noncoronavirus disease 2019-associated acute respiratory distress syndrome (9 [33.3%] vs 1 [4.3%]; p = 0.014). Those with coronavirus disease 2019, compared with those without, received more propofol prior to becoming hypertriglyceridemic (median, 5,436.0 mg [interquartile range, 3,405.5-6,845.5 mg] vs 4,229.0 mg [interquartile range, 2,083.4-4,972.1 mg]; p = 0.027). After adjustment for propofol dose with logistic regression (odds ratio, 5.97; 95% CI, 1.16-59.57; p = 0.031) and propensity score matching (odds ratio, 8.64; 95% CI, 1.27-149.12; p = 0.025), there remained a significant difference in the development of hypertriglyceridemia between coronavirus disease 2019-associated acute respiratory distress syndrome and noncoronavirus disease 2019-associated acute respiratory distress syndrome. There was no difference between groups in time to hypertriglyceridemia (p = 0.063). Serum lipase was not different between those who did or did not develop hypertriglyceridemia (p = 0.545). No patients experienced signs or symptoms of pancreatitis. CONCLUSIONS: Patients with coronavirus disease 2019 acute respiratory distress syndrome experienced a higher rate of propofol-associated hypertriglyceridemia than noncoronavirus disease 2019 acute respiratory distress syndrome patients, even after accounting for differences in propofol administration.
33354676	0	8	Propofol	Chemical	MESH:D015742
33354676	20	40	Hypertriglyceridemia	Disease	MESH:D015228
33354676	44	68	Coronavirus Disease 2019	Disease	MESH:D000086382
33354676	76	139	Noncoronavirus Disease 2019 Acute Respiratory Distress Syndrome	Disease	MESH:D012128
33354676	206	214	propofol	Chemical	MESH:D015742
33354676	226	246	hypertriglyceridemia	Disease	MESH:D015228
33354676	250	274	coronavirus disease 2019	Disease	MESH:D000086382
33354676	282	345	noncoronavirus disease 2019 acute respiratory distress syndrome	Disease	MESH:D012128
33354676	473	481	PATIENTS	Species	9606
33354676	483	491	Patients	Species	9606
33354676	497	532	acute respiratory distress syndrome	Disease	MESH:D012128
33354676	600	608	propofol	Chemical	MESH:D015742
33354676	683	691	patients	Species	9606
33354676	710	770	coronavirus disease 2019 acute respiratory distress syndrome	Disease	MESH:D000086382
33354676	1012	1020	Patients	Species	9606
33354676	1026	1097	coronavirus disease 2019-associated acute respiratory distress syndrome	Disease	MESH:D000086382
33354676	1127	1147	hypertriglyceridemia	Disease	MESH:D015228
33354676	1149	1161	triglyceride	Chemical	MESH:D014280
33354676	1181	1255	noncoronavirus disease 2019-associated acute respiratory distress syndrome	Disease	MESH:D012128
33354676	1303	1327	coronavirus disease 2019	Disease	MESH:D000086382
33354676	1372	1380	propofol	Chemical	MESH:D015742
33354676	1399	1419	hypertriglyceridemic	Disease	MESH:D064250
33354676	1572	1580	propofol	Chemical	MESH:D015742
33354676	1805	1825	hypertriglyceridemia	Disease	MESH:D015228
33354676	1834	1905	coronavirus disease 2019-associated acute respiratory distress syndrome	Disease	MESH:D000086382
33354676	1910	1984	noncoronavirus disease 2019-associated acute respiratory distress syndrome	Disease	MESH:D012128
33354676	2036	2056	hypertriglyceridemia	Disease	MESH:D015228
33354676	2142	2162	hypertriglyceridemia	Disease	MESH:D015228
33354676	2179	2187	patients	Species	9606
33354676	2221	2233	pancreatitis	Disease	MESH:D010195
33354676	2248	2256	Patients	Species	9606
33354676	2262	2322	coronavirus disease 2019 acute respiratory distress syndrome	Disease	MESH:D000086382
33354676	2352	2360	propofol	Chemical	MESH:D015742
33354676	2372	2392	hypertriglyceridemia	Disease	MESH:D015228
33354676	2398	2461	noncoronavirus disease 2019 acute respiratory distress syndrome	Disease	MESH:D012128
33354676	2462	2470	patients	Species	9606
33354676	2513	2521	propofol	Chemical	MESH:D015742
33354676	Positive_Correlation	MESH:D015742	MESH:D015228
33354676	Association	MESH:D015742	MESH:D000086382
33354676	Positive_Correlation	MESH:D015742	MESH:D064250
33354676	Negative_Correlation	MESH:D015742	MESH:D012128
33354676	Positive_Correlation	MESH:D014280	MESH:D000086382

